Tsuchihashi, Kenji
Ito, Mamoru
Okumura, Yuta
Nio, Kenta
Ozaki, Yukinori
Nishio, Hiroshi
Ichihara, Eiki
Miura, Yuji
Endo, Makoto
Yano, Shingo
Maruyama, Dai
Yoshinami, Tetsuhiro
Susumu, Nobuyuki
Takekuma, Munetaka
Motohashi, Takashi
Ochi, Nobuaki
Kubo, Toshio
Uchino, Keita
Kimura, Takahiro
Kamiyama, Yutaro
Nakao, Shinji
Tamura, Shinobu
Nishimoto, Hitomi
Kato, Yasuhisa
Sato, Atsushi
Takano, Toshimi
Baba, Eishi http://orcid.org/0000-0001-9428-6772
Article History
Received: 31 March 2024
Accepted: 21 April 2024
First Online: 2 May 2024
Declarations
:
: Kenji Tsuchihashi has received honoraria from Ono Pharmaceutical Co. Ltd., Chugai Pharmaceutical Co., Taiho Pharmaceutical Co. Ltd., and Novartis Pharmaceutical. K.K. Yukinori Ozaki has received honoraria from Daiichi Sankyo Co. Ltd., Pfizer Japan Inc., Chugai Pharmaceutical Co. Ltd., Eli Lilly Japan K.K., and Kyowa Kirin Co. Ltd. Eiki Ichihara has received honoraria from Eli Lilly Japan K.K. and research funding from MSD K.K., Ono Pharmaceutical Co. Ltd., Janssen Pharmaceutical K.K., and Takeda Pharmaceutical Co. Ltd. Yuji Miura has received honoraria from Ono Pharmaceutical Co. Ltd., MSD K.K., Takeda Pharmaceutical Co. Ltd., Eisai Co. Ltd., and Bristol Myers Squibb Co. Ltd., and research funding from MSD K.K. and Ono Pharmaceutical Co. Ltd. Shingo Yano has received research funding from Otsuka Pharmaceutical Co. Ltd. Dai Maruyama has received honoraria from Ono Pharmaceutical Co. Ltd., Janssen Pharmaceutical K.K., Nippon Shinyaku Co. Ltd., Eisai Co. Ltd., Mundipharma, Kyowa Kirin Co. Ltd., Chugai Pharmaceutical Co. Ltd., Zenyaku Holdings Co. Ltd., MSD K.K., SymBio Pharmaceutical Ltd., Sanofi K.K., AbbVie Inc., Takeda Pharmaceutical Co. Ltd., AstraZeneca K.K., Bristol Myers Squibb Co. Ltd., and Genmab K.K., and research funding from Amgen K.K., Astellas Pharma Inc., Biopharma Co. Ltd., Novartis Pharmaceutical K.K., Kyowa Kirin Co. Ltd., Ono Pharmaceutical Co. Ltd., Chugai Pharmaceutical Co., Janssen Pharmaceutical K.K., Takeda Pharmaceutical Co. Ltd., Otsuka Pharmaceutical Co. Ltd., Sanofi K.K., Bristol Myers Squibb Co. Ltd., AbbVie Inc., Eisai Co. Ltd., MSD K.K., Taiho Pharmaceutical Co. Ltd., AstraZeneca K.K., Eli Lilly Japan K.K., and Genmab K.K. Tetsuhiro Yoshinami has received honoraria from Kyowa Kirin Co. Ltd., Pfizer Japan Inc., Chugai Pharmaceutical Co., Eli Lilly Japan K.K., MSD K.K., AstraZeneca K.K., and Eisai Co. Ltd. Takashi Motohashi has received honoraria from AstraZeneca K.K., Chugai Pharmaceutical Co., and Myriad Genetics G.K. Toshio Kubo has received honoraria from Chugai Pharmaceutical Co. Takahiro Kimura has received honoraria from Sanofi K.K. Shinji Nakao has received honoraria from Kyowa Kirin Co., Ltd. Atsushi Sato has received honoraria from Chugai Pharmaceutical Co. and Taiho Pharmaceutical Co. Ltd., and a scholarship donation from Chugai Pharmaceutical Co. and Taiho Pharmaceutical Co. Ltd. Toshimi Takano has received honoraria from Daiichi Sankyo Co. Ltd., Chugai Pharmaceutical Co., and Eli Lilly Japan K.K. Eishi Baba has received honoraria from Chugai Pharmaceutical Co. Ltd. and Daiichi Sankyo Co.Ltd., and research funding from Taiho Pharmaceutical Co. Ltd. and Chugai Pharmaceutical Co. Ltd.